Dysregulation of cyclin D2 contributes to the pathogenesis of multiple myeloma, and can occur through translocations that activate MAF/MAFB or MMSET/FGFR3. However, cyclin D2 induction can also be seen in the absence of such translocations, such as in patients with hyperdiploid disease, through unknown mechanisms. In UniGene cluster data-mining and ECgene analysis, we found that zinc-finger with KRAB and SCAN domains 3 (ZKSCAN3), a novel transcription factor, is overrepresented in this malignancy, and three consensus ZKSCAN3 binding sites were found in the cyclin D2 promoter. Analysis of a panel of myeloma cell lines, primary patient samples and datasets from Oncomine and the Multiple Myeloma Genomics Portal (MMGP) revealed expression of ZKSCAN3 messenger RNA (mRNA) in a majority of samples. Studies of cell lines by western blotting, and of primary tissue microarrays by immunohistochemistry, showed ZKSCAN3 protein expression in a majority, and in a manner that paralleled messenger levels in cell lines. ZKSCAN3 overexpression was associated with increased gene copy number or genomic DNA gain/amplification in a subset based on analysis of data from the MMGP, and from fluorescence in situ hybridization studies of cell lines and primary samples. Overexpression of ZKSCAN3 induced cyclin D2 promoter activity in a MAF/MAFBindependent manner, and to an extent that was influenced by the number of consensus ZKSCAN3 binding sites. Moreover, ZKSCAN3 protein expression correlated with cyclin D2 levels in cell lines and primary samples, and its overexpression induced cyclin D2. Conversely, ZKSCAN3 suppression using small hairpin RNAs (shRNAs) reduced cyclin D2 levels, and, importantly, inhibited myeloma cell line proliferation. Finally, ZKSCAN3 was noted to specifically bind to oligonucleotides representing sequences from the cyclin D2 promoter, and to the endogenous promoter itself in myeloma cells. Taken together, the data support the conclusion that ZKSCAN3 induction represents a mechanism by which myeloma cells can induce cyclin D2 dysregulation, and contribute to disease pathogenesis.
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Introduction
Multiple myeloma is a malignant plasma cell disorder and the second most frequently diagnosed hematologic malignancy (Kyle and Rajkumar, 2008) . Significant progress has been made in understanding the molecular pathogenesis of myeloma. Many patients have nonhyperdiploid disease, and present with chromosomal translocations involving the immunoglobulin enhancer that dysregulate a cyclin D gene directly or indirectly. Examples of the former include cyclin D1, which is activated by t(11;14)(q13;q32) (Chesi et al., 1996; Gabrea et al., 1999) , and cyclin D3, which is activated by t(6;14)(p21;q32) (Shaughnessy et al., 2001) . Examples of the latter include cyclin D2, overexpression of which can be induced indirectly by dysregulation of the V-maf musculoaponeurotic fibrosarcoma oncogene homologs MAF and MAFB . These occur through the t(14;16)(q32;q23) and t(14;20)(q32;q11) (Chesi et al., 1998a; Hurt et al., 2004) translocations, respectively. Overexpression of cyclin D2 is also seen in other settings, such as in patients with t(4;14)(p16.3;q32) (Chesi et al., 1997; Hurt et al., 2004) , which dysregulates the Wolf-Hirschhorn syndrome candidate 1 (WHSC1, also known as MMSET), and the receptor tyrosine kinase fibroblast growth factor receptor-3 genes (Chesi et al., 1997 (Chesi et al., , 1998b . However, the mechanism of cyclin D2 induction in these cases, and in other non-hyperdiploid myelomas that overexpress cyclin D2 protein, is not known.
Up to one-half or more of patients do not harbor these translocations, and instead have a hyperdiploid karyotype (Hideshima et al., 2007) . As in non-hyperdiploid cases, cyclin D dysregulation is seen here as well, with patients having disease that overexpresses cyclin D1, D2, or both. This has led to the hypothesis that cyclin D dysregulation is an early unifying event in myelomagenesis . Indeed, the above findings have been used as the basis for the TC classification system, in which myeloma is divided into categories based on the type of translocation and cyclin D dysregulation present . However, although cyclin D1 overexpression is thought to be due to a gene-dose effect in hyperdiploid disease, the basis for cyclin D2 induction is not known. Thus, identification of novel mechanisms by which cyclin D isoforms can be dysregulated is important, as these could both contribute to disease pathogenesis and biology, and serve as therapeutic targets.
We previously identified the Zinc-finger protein with KRAB and SCAN domains 3 (ZKSCAN3) as a new 'driver' of colon cancer progression (Yang et al., 2008a) . Unbiased screening by cyclic amplification and selection of targets identified the DNA recognition motif (Yang et al., 2008b) . ECgene analysis indicated ZKSCAN3 was predominantly expressed in malignant bone marrow cells, and sequence analysis showed several binding sites upstream of the cyclin D2 promoter. These findings led us to evaluate the possibility that ZKSCAN3 could have a role in the pathogenesis of myeloma. In these studies, we found that ZKSCAN3 was overexpressed in a substantial proportion of myeloma cell lines and primary patient-derived samples, and in at least some this was associated with increased gene copy number. ZKSCAN3 bound and activated the cyclin D2 promoter and induced cyclin D2 expression, whereas its suppression reduced cyclin D2 levels, and inhibited myeloma proliferation. Based on these findings, we propose that ZKSCAN3 dysregulation is a novel mechanism used by myelomatous plasma cells to induce cyclin D2 expression.
Results

ZKSCAN3 is expressed in multiple myeloma
We previously identified ZKSCAN3 as a novel zincfinger transcription factor expressed in colon carcinoma (Yang et al., 2008a, b) . In querying the Unigene Cluster (Build 198, released 2007-01-13) and ECgene EST Expression databases (http://genome.ewha.ac.kr/ ECgene/; Supplementary Figure 1) , expressed sequence tags corresponding to ZKSCAN3 were found predominantly in myeloma and malignant marrow elements.
To directly evaluate the expression of ZKSCAN3, quantitative real-time PCR (qPCR) studies were performed on a panel of ten myeloma cell lines (Figure 1a) . ZKSCAN3 was expressed to at least some extent in all of the lines tested, whereas no ZKSCAN3 expression was detected in either normal CD19 þ B-cells, or normal CD138 þ plasma cells. Five of these cell lines with different ZKSCAN3 messenger RNA (mRNA) levels were then selected to evaluate protein expression (Figure 1b) . Western blotting indicated a correlation between mRNA and protein levels, in which U266 and ANBL-6 showed low ZKSCAN3 protein expression, whereas RPMI 8226 and KAS-6/1 cells revealed high levels of both.
Primary patient samples were then studied by qPCR utilizing banked CD138
þ -purified plasma cells. Among Figure 2A , patient #11 and #12), as was the case for normal hematopoietic elements. Additional tissue array slides were examined in which 4/4 myeloma patient samples showed strong ZKSCAN3 nuclear staining (Supplementary Figure 2B ). To rule out the possibility that this frequent detection of ZKSCAN3 overexpression was a result of our limited sample size, unbiased analysis using Oncomine datasets was performed. Affymetrix designed four probe sets representing the ZKSCAN3 complementary DNA (cDNA), but two of them (1562303_at and 1562305_x_at) were located in ZKSCAN3 genomic regions, and were therefore excluded from our analysis. The remaining two probe sets (Probe-1: 211773_s_at) and (Probe-2: 33952_at) mapped to the ZKSCAN3 3 0 -untranslated region, and a region covering part of the last coding exon and the 3 0 -untranslated region, respectively (Supplementary Figure 3A) . Interestingly, further analysis with Probes-1 and -2 showed that ZKSCAN3 was expressed in more than 93% of primary myeloma samples (Supplementary Figure 3B) . As ZKSCAN3 was not expressed in normal CD138 þ plasma cells, these findings support a possible role for ZKSCAN3 in myeloma pathobiology.
Gene copy number increases contribute to ZKSCAN3 overexpression The ZKSCAN3 locus at 6p22.1 has not been frequently reported to be amplified or translocated in myeloma, but it was of interest to examine this possibility, as 6p22 can be amplified or gained in other tumors (Santos et al., 2007) . Thus, we applied qPCR using 10, 20 and 40 ng of normal DNA input as a control, which exhibited dosage-dependent signal increases representing one, two and four gene copies, respectively (Figure 3a ). RPMI 8226 cells, which have high endogenous ZKSCAN3 expression, showed six copies of the ZKSCAN3 gene. KAS-6/1 cells, however, which showed comparable ZKSCAN3 expression, did not show obvious gene copy number changes, suggesting that other mechanisms may contribute to overexpression of this transcription factor. We then performed qPCR on the primary myeloma patient samples studied earlier, and found that 4/8 had evidence for ZKSCAN3 gene copy number gains from B1.5 to 2.8 ( Figure 3b ). Interestingly, the patient sample with the greatest ZKSCAN3 mRNA-expression level also had the highest gene copy number.
As our ZKSCAN3 copy number data were from a limited panel of samples, we then analyzed the possible presence of ZKSCAN3 gene amplification using the array comparative genomic hybridization (aCGH) datasets from the MMGP (http://www.broad.mit.edu/ mmgp/pages/portalHome.jsf). We performed a density plot analysis on the Mayo Clinic dataset, which contains 62 myeloma patients, and set up the threshold values using all segments from chromosome 6 to determine the copy number of segments as 'increased' and 'decreased' (Supplementary Methods). The analysis showed that the main mode of the density plot was at 1.942, very close to two copies, which represented 'no change.' Treating this component as a normal distribution, we estimated the mean and s.d. for this component alone, and determined that copy numbers less than 1.5262 represented gene loss, whereas values of more than 2.3584 represented a gain of gene copy number. Using these estimates, among all 62 patients, we observed that 6.5% (4/62) had decreased ZKSCAN3 gene copy number, whereas 58% (36/62) of patients showed increased ZKSCAN3 gene copy number (Supplementary Figure 4A ; Supplementary Table 1) .
Another MMGP aCGH dataset we analyzed was of 47 multiple-myeloma cell lines from the Mayo Clinic. Interestingly, we found that RPMI 8226 cells had the highest copy number for the ZKSCAN3-containing region (Supplementary Figure 4B ; Supplementary Table  2) , which is consistent with our qPCR data. We noticed that our studies supported that these cells had six ZKSCAN3 gene copies, whereas the Mayo Clinic dataset suggested 3.6 copies. This difference may be caused by the larger aCGH region in the Mayo dataset, causing the detection signal to be diluted, whereas our qPCR probe was designed to specifically detect ZKSCAN3.
Finally, to further evaluate the possibility that ZKSCAN3 sequences may be subject to amplification, interphase fluorescence in situ hybridization (FISH) studies were performed on primary samples using a nick-translated probe. To validate this probe, RPMI 8226 cells were used as a positive control, and did indeed show three signals ( Figure 3c , upper left panel), consistent with the above aCGH data. Ten consecutive unselected bone marrow aspirate samples from patients with myeloma were then analyzed, eight of which showed the expected two signals (Figure 3c , upper right panel). Two of these, however, showed three signals in 77.3 and 25.7% of 200 interphase nuclei analyzed, respectively (Figure 3c , lower right and left panel). These findings support the possibility that, at least in some cases, ZKSCAN3 overexpression may be due to increased gene copy number through gene amplification and/or gain.
ZKSCAN3 induces cyclin D2 expression
Sequence analysis of the cyclin D2 promoter revealed three putative ZKSCAN3 binding sites named ZK3-RE1, ZK3-RE2 and ZK3-RE3, respectively, conforming to the consensus KRDGGGGNNKDNNT sequence (Supplementary Figure 5A and B), suggesting that ZKSCAN3 may regulate cyclin D2 expression. We first examined the impact of ZKSCAN3 expression on the activity of the cyclin D2 promoter. HeLa cells were cotransfected with a vector expressing ZKSCAN3 and a cyclin D2 luciferase reporter construct (D2-luc), in which the promoter had either a wild type (wt) or mutant (mt) MAF binding site. MAF cDNA used as a positive control did induce substantial activity of the D2-MAFwt-luc construct, whereas the D2-MAF-mt-luc construct showed minimal induction (Figure 4a upper panel) . ZKSCAN3 cDNA activated transcription from the cyclin D2 promoter with a mt MAF site by approximately sixfold (Figure 4a upper panel) . Notably, a comparable extent of activation was seen in the wt construct, suggesting that ZKSCAN3 transactivated the cyclin D2 promoter in a MAF/MAFB-independent manner. As three putative ZKSCAN3-responsive elements (ZK3-RE1, ZK3-RE2 and ZK3-RE3) were found on the cyclin D2 promoter (Supplementary Figure 5A and B), we generated three mt cyclin D2-luc constructs, in which each ZKSCAN3 binding core GGGG sequence was replaced with ATAT (Supplementary Figure 5B) . HeLa cells were co-transfected with ZKSCAN3 cDNA and ZKSCAN3 binding site mt reporters (D2-mt1-luc, D2-mt2-luc and D2-mt3-luc, respectively). Interestingly, we observed that addition of ZKSCAN3 activated D2-mt1-luc and D2-mt3-luc to a lesser extent than D2-mt2-luc (Figure 4a, lower panel) . Also, a double-mt reporter in which ZK3-RE1 and ZK3-RE3 were simultaneously mutated showed little induction by ZKSCAN3 (Figure 4a , lower panel), suggesting that ZK3-RE1 and ZK3-RE3 are required for cyclin D2 transactivation.
To determine if cyclin D2 protein was also induced by ZKSCAN3, we reanalyzed the previously used tissue microarray slides, and a strong concordance was seen in all 10 samples studied between cyclin D2 and ZKSCAN3. Patients whose disease strongly expressed ZKSCAN3 also contained high levels of cyclin D2 (Figure 2b , upper panels), whereas patients who had myeloma that did not express ZKSCAN3 had low immunoreactivity with anti-cyclin D2 antibodies (Figure 2b, lower panel) . ZKSCAN3 and Cyclin D2 in myeloma L Yang et al
To demonstrate more directly that ZKSCAN3 induced cyclin D2, U266 cells, which have minimal basal ZKSCAN3 levels (Figure 1a and b), were transfected with ZKSCAN3 cDNA (Figure 4b ). Overexpression of ZKSCAN3 in U266 cells led to increased cyclin D2 mRNA ( Figure 4c ) and protein expression (Figure 4d ). Further confirmation that ZKSCAN3-induced cyclin D2 expression is dependent on its DNA binding capability was obtained by generating a ZKSCAN3 cDNA mt construct (ZKSCAN3-del), in which a stop codon was introduced between the KRAB and the first zinc-finger motifs, resulting in a truncated ZKSCAN3 protein with a molecular weight of B32 kDa (Supplementary Figure  6A) . Full-length and truncated ZKSCAN3 cDNAs were transfected into U266 cells by electroporation, and protein expression was verified by western blotting (Supplementary Figure 6B ). Cyclin D2 mRNA expression was then detected by qPCR and, as expected, ZKSCAN3-del failed to induce cyclin D2 mRNA (Supplementary Figure 6C) . The importance of ZKSCAN3 in cyclin D2 expression was next studied by suppressing ZKSCAN3 through infection of RPMI 8226 and KAS-6/1 cells with Lentiviral small hairpin RNA (shRNA) constructs. Among a panel of four different commercially available hairpins, only one shRNA construct gave consistent ZKSCAN3 knockdown by up to 50-55% (Supplementary Figure 7A) . Notably, cells transfected with this shRNA also showed suppression of cyclin D2 messenger levels (Supplementary Figure 7B) . However, the modest level of ZKSCAN3 knockdown led us to suspect the ZKSCAN3 and Cyclin D2 in myeloma L Yang et al possibility that this shRNA may have off-target, or non-specific effects. Thus, we designed six new shRNA sequences using the Dharmacon Custom siRNA Design Tool (Dharmacon, Lafayette, CO, USA), and generated the corresponding Lentiviral particles. Transduced RPMI 8226 cells were then examined for ZKSCAN3 expression by qPCR and, notably, one shRNA construct (shZK3-#1) showed B90% knockdown efficiency (Figure 5a, lane 3) , which was confirmed in KAS-6/1 cells as well (Supplementary Figure 7C) . These shZK3-#1 cells were then analyzed for cyclin D2 expression, and we consistently found significantly decreased cyclin D2 mRNA expression in the RPMI 8226 ( Figure 5b ) and KAS-6/1 (Supplementary Figure 7D) knockdown cells. In contrast, control shRNAs, or parental cells without shRNA transduction that did not reduce ZKSCAN3 expression, left cyclin D2 unaffected. Western blot analysis showed a corresponding decrease in expression of both ZKSCAN3 and cyclin D2 proteins in RPMI 8226 cells (Figure 5c ). Together, these findings support a specific role for ZKSCAN3 in regulating cyclin D2 expression.
Proliferation of myeloma cells after infection with ZKSCAN3-targeting shRNAs was then evaluated. RPMI 8226 cells infected with non-targeting controls grew comparably to parental cells (Figure 5d ). In contrast, cells infected with shZK3-#1, which reduced ZKSCAN3 (Figure 5a ) and cyclin D2 (Figure 5b ) expression, reduced proliferation (Figure 5d ). Notably, shZK3-#1 also led to growth retardation of KAS-6/1 cells (Supplementary Figure 7E) . As shRNAs can be prone to off-target effects, we transduced ANBL-6 cells with shZK3-#1 to detect if this shRNA had any offsite effects. Compared with RPMI 8226 cells, ANBL-6 transduced with shZK3-#1 did not show growthrate differences compared with non-targeting shRNAtransduced ANBL-6 cells (data not shown). To better understand the mechanism of myeloma cell growth retardation by shZK3-#1, cell cycle analysis was performed in RPMI 8226 cells transduced with shZK3-#1, and shNon-targeting controls, respectively, and stained with propidium iodide. Compared with non-targeting shRNAtransduced RPMI 8226 cells, shZK3-#1-transduced RPMI 8226 cells displayed significant increases in the G1 population (Figure 5e ), but decreases in the S and G2 phase populations, further supporting the role of shZK3-#1 in inhibiting cell proliferation.
Direct binding of ZKSCAN3 to the cyclin D2 promoter
If cyclin D2 is a bona fide direct ZKSCAN3 target, then the cyclin D2 regulatory region bearing the DNA motif identified by cyclic amplification and selection of targets should be bound by ZKSCAN3. Nuclear extracts from RPMI 8226 cells were therefore prepared and evaluated for their ability to bind an oligonucleotide spanning the most proximal putative binding site. In an electrophoretic mobility shift assay, a protein-DNA complex was detectable when the ZKSCAN3-specific probe was used (Figure 6a, lanes 3 and 7) . This was not the case when a mt oligonucleotide, in which the core ZKSCAN3 binding sequence was changed, was used ( Figure 6a , lane 8). Addition of anti-ZKSCAN3 antibodies produced a super-shifted signal (Figure 6a , lanes 5 and 6), which was not the case when pre-immune IgG was added (Figure 6a, lane 7) . Formation of the ZKSCAN3-DNA complex was reduced by an excess of cold probe competitor (Figure 6a, lanes 2 and 4) , but not with an unrelated competitor (Figure 6a, lane 3) .
To evaluate binding of ZKSCAN3 to the endogenous cyclin D2 promoter, chromatin immunoprecipitation assays were performed with chromatin prepared from KAS-6/1 and RPMI 8226 cells, and both specific and non-specific primers (Supplementary Figure 5A) . Anti-ZKSCAN3 antibodies preferentially precipitated RPMI 8226 sequences that were amplified with the specific primers (Figure 6b ), in comparison with the non-specific primers. Antibodies to ZKSCAN3 enriched chromatin spanning the DNA-binding motif more than 12 and fivefold, respectively, over that achieved with normal IgG (Figure 6c , specific primers), whereas the corresponding enrichment with primers distant from the ZKSCAN3 sites was modest (less than twofold; Figure 6c , non-specific primers). Together, these studies support the conclusion that the cyclin D2 promoter is indeed a direct ZKSCAN3 target.
Discussion
In this work, we report that the novel zinc-finger transcription factor ZKSCAN3 is overexpressed in a significant proportion of myeloma cell lines and primary patient samples (Figures 1 and 2 ; Supplementary Figures 1 and 2) , directly binds to and activates the cyclin D2 promoter (Figure 6 ), and induces cyclin D2 expression (Figure 4) . Thus, activation of ZKSCAN3 could represent one previously uncharacterized pathway utilized by myelomatous cells to induce cyclin D2. Indeed, our reporter assay implied that ZKSCAN3 activated cyclin D2 expression in a MAF/MAFBindependent manner (Figure 4) . However, further studies will be needed of the impact of MAF/MAFB knockdown in cells overexpressing ZKSCAN3 to allow this conclusion to be made more firmly. Another unresolved question is whether ZKSCAN3-mediated cyclin D2 expression is a common phenomenon in myeloma patients, or if it is found in only a subset of cases. Also, ZKSCAN3 expression was verified in a limited panel of patient samples that did not allow for correlation with specific myeloma cytogenetic subtypes, and such studies will need to be performed in a prospective manner using a large sample size to further define ZKSCAN3 expression. Nonetheless, taken together, our data allow us to conclude that ZKSCAN3 regulates cyclin D2 expression in at least a subset of myeloma cases.
The mechanism of ZKSCAN3 activation is another area for further investigation, as our initial studies suggested a contribution from gene copy number to the expression levels of this transcription factor in at least ZKSCAN3 and Cyclin D2 in myeloma L Yang et al some cases. RPMI 8226 cells, for example, harbored six gene copies (Figure 3 ), which could in part be a dosage effect as this line is known to harbor a trisomy 6, as well as several other complex aberrations involving chromosome 6. Similarly, one of eight primary samples showed an especially large ZKSCAN3 gene A total of 20 000 events were collected from each of three replicate experiments, and differences in cell cycle distribution determine using FlowJo software (Tree Star, Inc., Ashland, OR, USA) were compared using the Student's t-test.
ZKSCAN3 and Cyclin D2 in myeloma L Yang et al copy number (Figure 3) , whereas others showed elevations, though to lower levels. Trisomy of chromosome 6 has been reported in myeloma (Ferti et al., 1984) , and by FISH analysis may be present in up to 27% or more of patients (Perez-Simon et al., 1998) . Thus, in both cell lines and patient samples, one mechanism for ZKSCAN3 induction may be through trisomy 6 or other mechanisms, such as possibly amplification, to increase gene copy number. Indeed, gene copy number analysis with the MMGP datasets indicated the presence of amplification or gain of the ZKSCAN3 gene in a substantial proportion of patient samples (Supplementary Figure 4A) . Notably, other studies of cell lines and primary patient samples by aCGH have also revealed a Probe only + NE + wt Probe + 50x specific cold probe + NE + wt Probe + 50x non-specific cold probe + NE + wt Probe + 25x specific cold probe + + + + + NE + wt Probe + 2 µg anti-ZKSCAN3 NE + wt Probe + 6 µg anti-ZKSCAN3 NE + wt Probe + 6 µg normal IgG NE + mt Probe NE: nuclear extract; wt: wild-type; mt: mutant
Specific Primers
Non-specific Primers Specific primer Non-specific primer Figure 6 ZKSCAN3 binds directly to the cyclin D2 promoter. (a) Electrophoretic mobility shift assays were performed using the labeled specific oligonucleotide probe (lanes 1-7) , or a mutant probe (lane 8), to which were added RPMI 8226 nuclear extracts in binding buffer (lanes 2-8) or binding buffer alone (lane 1). Lanes 2 and 4 contained 50 Â and 25 Â unlabeled specific competitor oligonucleotide, respectively, whereas lane 3 contained a 50 Â non-specific competitor oligonucleotide. Lane 7 contained 6 mg of pre-immune IgG, whereas lanes 5 and 6 contained 2 and 6 mg of anti-ZKSCAN3 antibody, respectively. (b) Chromatin immunoprecipitation was performed using chromatin from RPMI 8226 cells and 2.5 mg of either the anti-ZKSCAN3 antibody, or an equivalent amount of pre-immune IgG. The primers used were indicated in the 'Materials and methods' section, whereas their location is diagramed in Supplementary Figure 5A . Each lane was loaded with nucleic acid input representing 10% of the total reaction mixture, whereas the negative control lacked chromatin input. (c) Chromatin immunoprecipitation of RPMI 8226 and KAS-6/1 cells was performed and evaluated using primers either spanning the cyclin D2 ZKSCAN3 binding sites (specific primers), or distant from the motif (nonspecific primers). Ct values are shown relative to that achieved with 10% input for each primer set, with data representing the average plus or minus the range of duplicate experiments. Negative controls lacked chromatin input.
ZKSCAN3 and Cyclin D2 in myeloma L Yang et al gain of sequences in the 6p region in general (Gutierrez et al., 2004; Carrasco et al., 2006) , and at 6p22.1-25.3 in particular (Largo et al., 2007) . These data suggest that trisomy 6 may not be the key factor contributing to ZKSCAN3 gene copy number increase. Meanwhile, we also noticed that ZKSCAN3 expression was seen in KAS-6/1 at levels comparable with those seen in RPMI 8226 cells (Figure 1 ), but without an increased gene copy number (Figure 3) . One mechanism may be through translocation of ZKSCAN3 at its 6p22.1 locus along with cyclin D3 at 6p21.1 near an immunoglobulin enhancer that could dysregulate both, but KAS-6/1 cells do not harbor this translocation, and do not express cyclin D3 (Arora and Jelinek, 1998) . Thus, other mechanisms beyond gene copy number increase and/or translocations must be available to myeloma cells to induce ZKSCAN3 expression. It is conceivable that cyclin D2 is not the only target gene for ZKSCAN3 in myeloma, especially in light of our previous studies showing that vascular endothelial growth factor is a target of ZKSCAN3 in colon cancer (Yang et al., 2008a, b) . A variety of studies have shown a critical role for angiogenesis in general, and vascular endothelial growth factor in particular, in myeloma. For example, increased bone marrow microvessel density has been correlated clinically with disease progression and poor prognosis, and vascular endothelial growth factor also exerts direct effects on myeloma cell migration, proliferation, survival and drug resistance (Podar et al., 2001; Kumar et al., 2003; Le Gouill et al., 2004; Ria et al., 2004; Markovic et al., 2008; Yang et al., 2008b) . Additional studies are underway to evaluate the role of ZKSCAN3 in vascular endothelial growth factor induction in myeloma, to verify whether ZKSCAN3-mediated cyclin D2 expression occurs in a MAF/ MAFB-dependent/independent manner, and also to fully evaluate the role of this novel gene in myeloma pathogenesis through appropriate animal models.
Materials and methods
Cell lines and primary samples
Myeloma cell lines were propagated as previously described , whereas HeLa cells were maintained in similarly supplemented modified Eagle medium. Primary cells were obtained through the Department of Lymphoma/ Myeloma Tissue Bank, and collected as marrow aspirates after informed consent was obtained in accordance with the Declaration of Helsinki. Mononuclear cell fractions were prepared by density gradient centrifugation, and malignant cells were isolated by CD138 þ selection (Miltenyi Biotec, Inc., Auburn, CA, USA). The current studies on de-identified aliquots were performed according to an Institutional Review Board-approved protocol. Normal human CD19 þ B-cell total RNA was from Miltenyi Biotec, Inc., and plasma cell cDNA was from AllCells LLC. (Berkeley, CA, USA).
Constructs
The cyclin D2 promoter reporters (D2-luc) containing wt or mt MAF binding sites were kindly provided by Dr Louis Staudt (Metabolism Branch, Center for Cancer Research, National Cancer Institute). The wt D2-luc was subjected to site-directed mutagenesis to mutate ZKSCAN3 binding sites using the QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies, Inc., Santa Clara, CA, USA). pBluescriptR-MAF (Open Biosystems, Huntsville, AL, USA) was used to subclone MAF cDNA to the pLVX vector, whereas the pLVTHM Lentiviral vector was kindly provided by Didier Trono (Ecole Polytechnique Fe´de´rale de Lausanne, Lausanne, Switzerland).
Nucleofection
Transfection of pIRES2-EGFP-ZKSCAN3 or the vector control was performed using the Amaxa Cell Line Optimization Kit (Lonza, Basel, Switzerland), and transfected cells were selected in G418.
Cell proliferation and cell cycle analysis Cellular proliferation was evaluated using the tetrazolium reagent WST-1 (Roche Diagnostics Corp., Indianapolis, IN, USA) as previously described . For cell cycle studies, cells were seeded at the same initial density, fixed after 48 h, stained with 50 mg/ml of propidium iodide with RNaseA, and incubated at 37 1C before analysis.
qPCR Expression of ZKSCAN3 and cyclin D2 mRNA were determined in triplicate using an ABI PRISM 7900 HT Sequence Detection System (Life Technologies Corporation, Carlsbad, CA, USA) by the TaqMan Gene Expression Assay (Life Technologies Corporation) with b-actin or glyceraldehyde phosphate dehydrogenase as controls. To determine the ZKSCAN3 gene copy number, whole genomic DNA was analyzed by File Builder v3.1 software (Life Technologies Corporation). DNA regions without repeat elements or low complexity DNA were selected to do basic local alignment search tool searches for sequence similarity, and a sequence 41000 bp unique to ZKSCAN3 was selected to design qPCR primers with the RNase P1 gene as an internal control. Genomic DNA was made with the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA), with normal human white blood cells as a control. qPCR was performed with 10 ng of genomic DNA using an ABI PRISM 7900 HT Sequence Detection System. 
Immunohistochemistry
Tissue microarray slides were from Biomax, Inc. (Rockville, MD, USA). Immunohistochemistry was performed as previously described (Yang et al., 2008b) .
Electrophoretic mobility shift assays Nuclear extract (10 mg) was mixed with 0.6 mg of poly(dI/dC), 2 Â 10 4 c.p.m. of g-32 P-labeled oligonucleotide, and, where indicated, anti-ZKSCAN3 (2 and 6 mg) or pre-immune IgG (6 mg). The wt cyclin D2 oligonucleotide sequence was 5 0 -TTCTAAAATCACCCCCTCCCTTAT-3 0 , and the mt was 5 0 -TTCTAAAATCACTATAATTCTTAT-3 0 spanning the putative ZKSCAN3 binding motif in the cyclin D2 promoter.
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Chromatin immunoprecipitation assays
Chromatin immunoprecipitation assays were performed using the ChIP-IT Kit (Active Motif, Carlsbad, CA, USA). Specific primers targeted the ZKSCAN3 binding motif at À482 to À495 nucleotides upstream from the cyclin D2 promoter (5 0 primer: 5 0 -CTGGTCCCTTTAATCGGGGC-3 0 ; 3 0 primer: 5-GATCCTAATCCTCCTGCCCTTG-3 0 ). Non-specific primers targeted a region of the cyclin D2 promoter without ZKSCAN3 binding sites that was 43kb away (5 0 primer: 5 0 -GCAGGGAGGAATATGTCGCG-3 0 ; 3 0 primer: 5 0 -ATCT TCCACCCCCAAGCAGT-3 0 ) (Supplementary Figure 5A) . For primer design, the cyclin D2 promoter sequence was analyzed by the File Builder v3.1 software (Applied Biosystems, Carlsbad, CA, USA) and basic local alignment search tool to exclude repeat elements, low complexity DNA and regions with sequence similarity. The resulting promoter sequences spanning or distant from the ZKSCAN3 binding sites were chosen to design specific and non-specific TaqMan primers, respectively.
ZKSCAN3 knockdown ZKSCAN3 shRNAs were generated using the Dharmacon Custom siRNA Design Tool and sub-cloned into pLVTHM with a green fluorescent protein selection marker. One shRNA that showed effective knockdown targeted the sequence 5 0 -CCACCTGAGAGAAGACATT-3 0 in the ZKSCAN3 open reading frame. The corresponding Lentivirus was produced by transfecting human embryonic kidney cells (293FT; Invitrogen, Carlsbad, CA, USA) with pLVTHM containing the ZKSCAN3-shRNA or non-targeting shRNA sequences, the packaging plasmid (MD2G), and the envelope plasmid (PAX2). To silence ZKSCAN3, myeloma cells plated at 1 Â 10 6 in six-well plates were transduced with the virus, and after 16 h, the virus-containing medium was replaced with normal growth medium. Transduced cells were sorted by analysis for green fluorescent protein expression.
Western-blot analysis
Protein expression in ZKSCAN3 knockdown cells was measured by western blotting (Yang et al., 2008a, b) . Antibody to cyclin D2 was purchased from Cell Signaling Technologies (Danvers, MA, USA) whereas anti-b-actin was from SigmaAldrich (St Louis, MO, USA).
Luciferase reporter assays
HeLa cells were transfected with the indicated plasmids, and cell lysates were probed using the Luciferase Assay System (Promega Corporation, Madison, WI, USA). Data were obtained from at least three sets of transfections, and are presented as the mean with the s.d.
FISH
FISH studies for ZKSCAN3 were performed according to previously described procedures (Chang et al., 2006) . Briefly, bacterial artificial chromosome clones were purchased from the Children's Hospital Oakland Research Institute, and sequencing verified that clone RP11-245E14 contained full-length ZKSCAN3. The DNA was then labeled with SpectrumGreendUTP using the Nick Translation Kit (Abbott Molecular, Abbott Park, IL, USA), and the probe was validated to confirm the ZKSCAN3 location at 6p22.1 using one positive control (RPMI 8226 cells), and 10 normal samples. Interphase nuclei in marrow aspirates from 10 randomly selected myeloma patients were then analyzed by FISH, and a minimum of 200 interphase cells were analyzed for each probe. Only samples that contained three or more FISH signals in 410.3% of cells were considered positive for ZKSCAN3 amplification (Lu et al., 2010) .
